World Journal of Pharmaceutical Science and Research

www.wjpsronline.com

Review Article

ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 8
Page: 223-227

A CONCISE REVIEW ON ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL SCIENCES

M. Ashok babu*, Bharathi G., A. Aparna, P. Swathi

Assistant Professor, Dept. of Pharmaceutical Analysis & QA, SSJ College of Pharmacy for women's, Hyderabad, India.

Article Received: 04 June 2026 | | ***Article Revised: 25 June 2026*** | | ***Article Accepted: 16 July 2026***

***Corresponding Author: M. Ashok babu**
Assistant Professor, Dept. of Pharmaceutical Analysis & QA, SSJ College of Pharmacy for women's, Hyderabad, India.
DOI: https://doi.org/10.5281/zenodo.21704439

How to cite this Article: M. Ashok babu, Bharathi G., A. Aparna, P. Swathi (2026) A CONCISE REVIEW ON ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL SCIENCES. World Journal of Pharmaceutical Science and Research, 5(8), 223-227.

ABSTRACT

The pharmaceutical industry is changing fast, and the list of AI applications being integrated is growing daily, changing virtually every aspect of pharmaceutical processes from drug discovery to delivery. Artificial intelligence in pharmaceuticals can be applied across many different operations, such as drug discovery, clinical trials, and supply chain optimization, in addition to increasing speed and accuracy, it offers new avenues for individualized treatment and innovative therapeutic solutions.

KEYWORDS: Artificial Intelligence, Pharmaceutical Sciences.

INTRODUCTION

The goal of Artificial Intelligence (AI) is to imitate the intellectual activities of people. The subfield of machine learning (ML) allows computers to better themselves through experience. The branch known as deep learning (DL) is one form of ML that uses artificial neural networks (ANNs) to carry out the processing of large amounts of data using multilayered nonlinear units. By imitating the structure of the brain, ANNs perform recognition, classification, and learning.[4]

Computer and technological developments permeated every aspect of science. Artificial Intelligence (AI), the basic field of computer science, has infiltrated different fields from engineering to medicine.[3] Traditional methods of drug design are increasingly being replaced by computer-aided approaches to drug design. Artificial intelligence is widely used to improve design methods and shorten the development time of medicines. In addition, AI makes it easier to identify target proteins, improving the success rate of new drugs.[1-3] AI offers considerable potential for identifying and

developing new drugs. Recently, different machine learning methods have emerged, some of which can be classified as domain-specific artificial intelligence, and are being used effectively in drug discovery and design.

Artificial Neuronal Network in Design of controlled release drug delivery systems

In recent years, Artificial Neural Networks (ANNs) have emerged as compelling models to imitate the human brain and performing brain-like processes of information processing. Drug delivery represents many aspects, including the interaction of drugs with cell membranes and molecules, toxicity, negative effects that can result from the drug intake, as well as timing and dosage of medication release.[1] Successful drug delivery relies on the existing knowledge concerning the physicochemical properties of the medications being utilized. In this context, it is worth noting that certain medical properties have a certain amount of influence over the medication effectiveness. Solubility, permeability, transport-related argumentation as well as metabolic stability represent various parameters, which can have a measurable impact on the success of the drug.[2] The lack of permeability of drugs can hinder the evaluation of results obtained from both cell tests and quantitative structure-activity relationship (QSAR) models. Moreover, rapid clearance has resulted in short half-lives, continuously decreasing exposure, and the drug efficacy problems Drug development process.[5]

Management of networks using AI and ML

Machine learning (ML) and artificial intelligence (AI) are revolutionizing several sectors by allowing devices to gain insight and perform work automatically without explicit direction. AI and ML can assist in data processing, predicting potential drug interactions, and enhancing clinical trial designs while accelerating the time to introduce new drugs to the market after the completion of clinical trials and decreasing expenses. Nevertheless, effectiveness of AI is still limited in pharmaceutical industry due to strict regulations and necessity of having human oversight.[6]

AI Application in the Pharmaceutical Industry

The importance of artificial intelligence in the analysis of omics data cannot be emphasized enough. Omics data refers to the whole range of biological information available through genome, transcriptome, proteome, and metabolome networks.[4] AI makes it possible to mix various omics calls, including those related to DNA variations, protein amount, and metabolite concentration, into one coherent picture. Moreover, the AI that maps protein–protein interactions and disease pathways makes it possible to find many targets and mechanisms of action at once.[7,8]

AI in Manufacturing & Operations

When it comes to pharmaceutical production, AI plays an important role in optimizing processes, maintenance activities and quality assurance. The whole manufacturing process including handling raw materials, formulating drugs and packaging can be done through AI systems which can automate the tasks with extremely high accuracy and consistency. Additionally, it is worth noting that machine-learning systems can analyze great amounts of data due to collecting information from monitoring devices and thus timely reveal abnormalities and apply corrections. Overall, AI-enabled automation improves efficiency of production and lowers defects.[9]

Clinical Research

The human clinical trials that are conducted in order to approve new drugs are complicated and long processes, which begin with animal research and eventually include people. The trials are costly, costing billions of dollars and taking anywhere from several years to more than ten years to conduct. Additionally, patients are likely to go through effects

which they did not know they would experience during the trial. The new drug development process entails human clinical trials, which is a long and complex process, starting with animal experiments and ending with people being used as test subjects. The entire process is extremely costly, amounting to billions of dollars, taking as long as several years up to more than a decade.[10]

AI in Drug Screening

In recent years, research studies have been conducted that consider combining various kinds of biomedical data such as chemical compounds, protein sequences, expression patterns, and clinical trial results into a common artificial intelligence model. It is assumed that the implementation of multimodal learning architectures will lead to predictions being made on the basis of several sources of correlation.[11]

Utilization of Quantum Computing:

Quantum algorithms are new but will have the potential to model molecular processes accurately.[12]

AI in quality assurance at Pharmaceutical Industry

The pharmaceutical industry includes a large number of professionals for quality assurance purposes responsible for protecting the safety, efficacy, and consistency of drugs.AI robotics makes equipment certification easier by reducing human interference and therefore aiding productivity while abiding by strict regulation.[13-14]

Artificial intelligence makes significant contributions towards this process with advanced modeling methodologies including multivariate analysis as well as digital twins. These methodologies effectively enable simulations of different scenarios associated with this process and thus eliminate the need for physical tests.[11] Furthermore, the algorithms employed by the artificial intelligence may enhance the design of the test and minimize the number of test runs required. AI allows pharmaceutical organizations to ensure shorter validation times with minimized costs and an increase of confidence.[15]

(1) Automation testing: AI-based tools for test automation improve feedback cycle time and increase software quality by decreasing testing times.
(2) Identifying defects: Using AI technology, defects and/or defects in production process can be detected.
(3) Anticipative maintenance: AI-enabled anticipatory analytics allows for real-time monitoring of equipment, lower downtime, and better maintenance strategies to be developed.
(4) Image and video recognition: AI technology can process visual information and detect defects in products and production processes.
(5) Natural Language Processing for compliance: NLP technologies allow companies operating in regulated industries to comply with regulations.[16]

AI in Pharmaceutical marketing[17]

The use of AI technology helps pharmaceutical marketers analyze large amounts of data, such as prescribing patterns, demographics, and behavioral trends, and helps classify both healthcare professionals and clients.AI tools allow to analyze the type of information that different clients consume: emails, webinars, social networks, or websites. Based on that, AI generates customized messages that are suited to the preferences and needs of individual clients.[17]

Therefore, such personalization contributes to product promotion. Furthermore, AI technology allows pharmaceutical marketers to track the performance of their campaigns in real time. Compliance is critical for pharmaceutical marketers due to the high regulation of the industry. AI enables to analyze promo materials for compliance with both legal and ethical requirements. It minimizes the chances of violating regulatory norms and helps marketers stay within the limits.

In general, we can conclude that AI improves the responsiveness and efficiency of pharmaceutical marketing and makes the marketing process customer-oriented.[18]

CHALENGES OF AI

The application of AI technologies at different process stages will enable the transformation of the pharmaceutical sector in a considerable way. Nevertheless, there are a number of challenges and considerations that accompany the successful application of the processes. Let us explore the details.[19]

a. Concerns on data privacy and security
b. Integration with current systems and workflows
c. Ethical implications in AI decision making
d. Regulatory and law compliance issues
e. Professional expertise

Skilled Personnel

To effectively implement and operate AI technology, a skilled workforce must be employed. Data scientists, AI experts and other workers with AI and machine learning experiences will be involved in developing and managing these technologies.[20]

CONCLUSION

The advancement of AI technologies has introduced a number of innovations to the process of drug discovery, drug development, and the delivery of personalized medication in the Pharmaceutical Industry by facilitating data processing and improving efficiency. Within the sector, AI is being used to reduce time spent on identifying medications and improve clinical research and trials with advantages for the treatment of patients.

AI and ML are very useful but the implementation of these technologies in the pharmaceutical industry requires dealing with a multitude of rules, ethical concerns, as well as facilitating human-AI cooperation. The present collaborations between pharmaceutical firms and AI businesses will further enhance the advancement of drug discovery and patient treatment.

REFERENCES

1. Nikhil Singh*, Sunil Kumar, K. Prabhu, Aman Shukla, Ashish Yadav, A Review on Artificial Intelligence in Pharma; Int. J. Pharm. Sci. Rev. Res., ISSN: 0976 – 044X, 84(1) - January 2024; Article No. 06, Pages: 33-39.
2. T. M. Tilva *, A. R. Sorthiya, M. A. Vaghasiya, P. A. Khanpara and S. D. Faldu,A REVIEW ON SCOPE OF ARTIFICIAL INTELLIGENCE IN PHARMA,IJPSR, 2024; 15(9); 2635-2646.
3. Nikhil Singh*, Sunil Kumar, K. Prabhu, Aman Shukla, Ashish Yadav, A Review on Artificial Intelligence in Pharma; Int. J. Pharm. Sci. Rev. Res., ISSN: 0976 – 044X, 84(1) - January 2024; Article No. 06, Pages: 33-39.

4. Bhargav Eranti, Singamaneni Premika, Mandala Rohitha, Meka Sai Geetha, A Vamsi Krishna, Nadimipalli Rakshith and Kavya Turaga, Artificial neuron network in pharma: Revolutionizing drug development optimization and smart manufacturing a comprehensive review; ORIENTAL JOURNAL OF CHEMISTRY, ISSN: 0970-020 X; 2025; 41(3): 873-879
5. Huzefa A Ujjainwala, Drug delivery using artificial neural networks (ANNs) – A concise overview, African Journal of Medicine and Pharma Research, 2025; 3(2): 63-64.
6. Rupali Madhav Thakare1, Pooja Gangurde2 Gauri Suresh Sawant, Machine Learning and Artificial Intelligence in Pharmaceutical Industry and Development, International Journal for Multidisciplinary Research (IJFMR, E-ISSN: 2582-2160, November-December 2024; Volume 6, Issue 6.
7. Fatima I, Rehman A, Ding Y, Meng Y, Rehman HU, Warraich DA, et al. Breakthroughs in AI and multi-omics for cancer drug discovery: A review. Eur J Med Chem, 2024; 280: 116925.
8. https://lifesciences.danaher.com/us/en/library/ai-in-pharmaceutical-industry.html
9. Rathore AS, Nikita S, Thakur G, Mishra S. Artificial intelligence and machine learning applications in biopharmaceutical manufacturing. Trends Biotechnol, 2023; 41(4): 497-510.
10. https://ca-hwi.org/public/uploads/pdfs/ArtificialIntelligenceinHealthcare.pdf
11. inay Makhija,2Bhuvi Saini,3Dr. Sunil Kumar Shrivastav,4Dr. Kashish Parwani, AI IN DRUG DISCOVERY: A Comprehensive Review ; The Chitransh Academic & Research, September 2025; Volume 1| Issue 04 |.
12. https://thechitranshacadmic.in/wp-content/uploads/2025/10/paper-8-sep.pdf
13. Saha GC, Eni LN, Saha H, et al. Artificial intelligence in pharmaceutical manufacturing: Enhancing quality control and decision making. Riv Ital Filosofia Anal Junior, 2023; 14(2): 116-126
14. Waqar M, Bhatti I, Khan AH. AI-powered automation: Revolutionizing industrial processes and enhancing operational efficiency. Rev Intel Artif Med, 2024; 15(1): 1151- 1175.
15. Rahman SN, Katari O, Pawde DM, et al. Application of design of experiments® approach-driven artificial intelligence and machine learning for systematic optimization of reverse phase high performance liquid chromatography method to analyze simultaneously two drugs (cyclosporin A and etodolac) in solution, human plasma, nanocapsules, and emulsions. AAPS PharmSciTech, 2021; 22(4): 155
16. Vaibhav Adhao, Jaya Ambhore, Shreyash Chaudhar, Transforming pharmaceutical quality assurance and validation through artificial intelligence, Artificial Intelligence in Health; 2026; 3(1).
17. Shraddha Dingre * , Vishal Girbane, Sujit Garudkar, Priyanka Todakari, Dhanashri Borawake and Meera Deshmukh, Integrating artificial intelligence in pharmaceutical marketing: Enhancing engagement and efficiency, World Journal of Advanced Engineering Technology and Sciences, 2025; 15(03): 526-539.
18. S. B. Junaid et al., “Recent Advancements in Emerging Technologies for Healthcare Management Systems: A Survey.,” Healthcare (Basel), Oct. 2022; 10(10). doi: 10.3390/healthcare10101940.
19. https://www.datacamp.com/blog/ai-in-pharmaceuticals
20. https://www.datacamp.com/blog/ai-in-pharmaceuticals